KR20190064715A - Composition for treating or preventing thyroid disorders comprising laminaria japonica extract and astragalus mimbranaceus extract - Google Patents

Abstract

The present invention relates to a composition for treating, alleviating or preventing thyroid disorders containing at least one extract selected from a group consisting of a Saccharina japonica extract and an Astragalus propinquus extract, specifically a mixture of the Saccharina japonica extract and the Astragalus propinquus extract as an active component. The composition for treating, alleviating or preventing thyroid disorders according to the present invention uses Saccharina japonica and Astragalus propinquus as extract objects and uses an extract which uses water, the most harmless extract solvent, as a raw material, thereby having no side effects. In addition, the composition is most effective in treating hypothyroidism, thereby being usefully used for treating, preventing or alleviating hypothyroidism.

Description

TECHNICAL FIELD [0001] The present invention relates to a composition for treating or preventing thyroid disease, which comprises as an active ingredient an alginate extract and a sea tangle extract. [0002] The present invention relates to a composition for treating or preventing thyroid disease,

The present invention relates to a composition for treating, ameliorating or preventing thyroid disease, specifically, a composition for treating, ameliorating or preventing thyroid disease, comprising a component derived from a natural product as an active ingredient.

Thyroid is an endocrine organ that produces iodine as a raw material and secretes thyroid hormone into the bloodstream. Thyroid hormones control the rate of metabolism in our bodies. The most important of these thyroid hormones is thyroxine called T4 (four iodine atoms) and triiodothyronine called T3 (three iodine atoms). These hormones regulate various metabolism processes that the body maintains itself, such as the growth and development of the body and the production of carbohydrates, proteins and lipids necessary for the human body. It also promotes metabolic processes to generate energy, which generates heat, which is involved in body temperature control, so that all institutions maintain proper functioning

Recently, the number of patients with thyroid disease is rapidly increasing. One of the main causes of thyroid disease is abnormal secretion of thyroid hormone.

For the secretion of thyroid hormones in the body, thyroid stimulating hormone (TSH) should be secreted from the pituitary gland. It is regulated by feedback. Specifically, when the secretion of TSH is suppressed, the stimulation of hormone secretion is reduced in the thyroid gland, resulting in insufficient thyroid hormone, which promotes secretion of TSH from the pituitary gland. Thus, thyroid hormone secretion . Conversely, when TSH secretion is promoted, excess thyroid hormone is secreted, which inhibits the secretion of TSH from the pituitary gland and suppresses thyroid hormone secretion.

Hyperthyroidism and hypothyroidism are the most common disorders associated with abnormal thyroid hormone secretion. Hyperthyroidism refers to all diseases with symptoms that occur when thyroid hormones are overdosed into the blood. The main features of hyperthyroidism are thyroid hyperplasia, increased basal metabolic rate, and malfunction of the autonomic nervous system. According to recent statistics, women are more likely to develop at a ratio of 4: 1 compared to men, To 50 generations.

Hypothyroidism is a general term for all diseases caused by lack of production of thyroid hormones. Hypothyroidism is usually a very slowly progressive disease, and it is often difficult to recognize. The symptoms vary widely depending on the progression of the disease, but generally the metabolic status of our body is reduced, making it easily fatigued and helpless. Is lost, becomes cold sensitive, increases in weight, causes symptoms such as memory loss, loss of appetite, muscle aches, arthralgia, decreased sweating

Most of thyroid diseases including hypothyroidism are related to thyroid hormones. Therefore, in order to treat thyroid diseases at present, hormones and the like must be supplied from outside to the body, The risk of ischemic heart disease induction such as myocardial infarction or unstable angina, and changes in the body's demand for thyroid hormone have been reported.

Therefore, it is required to develop a therapeutic agent for thyroid disease which has fewer side effects and is easier to apply.

10-1543775B 10-1636345B 10-1621446B 10-1732029B 10-1520417B

It is an object of the present invention to provide a composition for treating, ameliorating or preventing thyroid disease, which comprises a natural product effective for treating, preventing or improving thyroid disease.

In order to achieve the above object, the present invention provides a composition for improving or preventing thyroid disease. The composition for improving or preventing the thyroid disease may be a food composition.

More specifically, the present invention relates to a method for producing kelp japonica ) and Emperor ( Astragalus The present invention also provides a food composition for improving or preventing thyroid diseases, which comprises at least one extract selected from the group consisting of membranaceus , as an active ingredient.

The extracts of at least one selected from the group consisting of kelp and yanggi are prepared by adding water to a mixture of hydrothermal extracts of a mixture of sea tangle and ylang-ylang mixture, preferably sea tangle and yellow sea tangle, in a weight ratio of 3: 1 (kelp: ylang ylang) May be extracted by an extraction method.

The thyroid disease may be hypothyroidism.

The food composition for improving or preventing the thyroid disease may be a health functional food for improving or preventing thyroid disease.

The present invention also provides a composition for treating or preventing thyroid disease. The composition for improving or preventing the thyroid disease may be a pharmaceutical composition.

More specifically, the present invention relates to a method for producing kelp japonica ) and Emperor ( Astragalus The present invention also provides a pharmaceutical composition for the treatment or prevention of thyroid disease, which comprises as an active ingredient at least one extract selected from the group consisting of membranaceus .

The extracts of at least one selected from the group consisting of kelp and yanggi are prepared by adding water to a mixture of hydrothermal extracts of a mixture of sea tangle and ylang-ylang mixture, preferably sea tangle and yellow sea tangle, in a weight ratio of 3: 1 (kelp: ylang ylang) May be extracted by an extraction method.

The thyroid disease may be hypothyroidism.

The inventors of the present invention have found that, in order to develop a plant component that exhibits an excellent thyroid dysfunction improving effect but does not cause side effects such as side effects such as synthetic drugs and antithyroid preparations used in conventional hormone replacement agents, , And 70 kinds of herbal medicines and 30 kinds of seaweeds, which are used for long time as herbal medicines or foods, and proved to be safe, the seaweed extract and hwanggi extract have remarkably superior thyroid function improvement And has not been found to cause hepatotoxicity or hyperthyroidism. Based on this finding, the present invention has been completed.

As used herein, unless otherwise specified, an active ingredient refers to a composition that provides a therapeutic, ameliorative, or prophylactic effect, particularly an estrogen-like or estrogen-like activity, of a thyroid disease in a composition, particularly a pharmaceutical composition or a food composition .

As used herein, the term " extract " means an extract obtained by treating an extractive solvent with a plant or a product prepared by the method of producing an extract, unless otherwise specified. The extract may be formulated ) Results.

The extract has the meaning of being used as a crude extract, but broadly includes fractions obtained by further fractionating the extract. Specifically, the above-mentioned extract includes not only an extract obtained by using an extraction solvent, but also an extract obtained by additionally applying a purification process thereto. For example, the extract may contain a fraction obtained by passing the extract through an ultrafiltration membrane having a constant molecular weight cut-off value, a fraction obtained by various chromatographies (prepared for separation according to size, charge, hydrophobicity, or affinity) Further comprising fractions obtained through various purification methods.

Unless otherwise specified herein, treatment or amelioration refers to any action whereby the symptoms of the thyroid disease are alleviated or beneficially altered upon administration of the composition of the present invention.

As used herein, " prophylactic " means any action that inhibits the symptoms of thyroid disease upon administration of the composition of the present invention, unless otherwise specified herein.

In this specification, unless otherwise indicated, administration means to provide any desired composition of the invention to the subject by any suitable method.

As used herein, unless otherwise specified, an individual refers to any animal, particularly a mammal, including humans, monkeys, dogs, goats, pigs or rats, who have had thyroid disease by administering the composition of the present invention.

Hereinafter, the present invention will be described in more detail.

The present invention relates to a composition for improving or preventing thyroid disease. The composition for improving or preventing the thyroid disease may be a food composition for improving or preventing thyroid disease.

The composition for improving or preventing the thyroid disease may include one or more extracts selected from the group consisting of kelp and yellow radish as an active ingredient.

The kelp ( Laminaria japonica ) may preferably be wrapped. This packing has been traditionally used to treat a variety of gall diseases including goitre from 1,500 years ago in East Asia, including Korea, by drying the outpost of kelp. The kelp is a very safe substance listed as a seasoning in Generally Recognized as Safe (GRAS), and is one of the most common seaweeds used for food in East Asia such as Korea, Japan, and China.

The Astragalus membranaceus ) is a medicinal plant belonging to the soybean family and is mainly used as a medicine by drying the roots. The Hwanggi is one of the traditional medicines that have been used for treating cold, diarrhea, fatigue, and edema in Oriental medicine and has been shown to have antioxidant, anti-inflammatory and immunostimulatory effects

The extract of at least one selected from the group consisting of kelp and kelp may be one prepared by a conventional method for producing a plant extract, and examples thereof include at least one kind selected from the group consisting of kelp and yellow kelp, a dried product thereof or a pulverized product thereof , Extracting the juice with an extraction solvent, or extracting the extract with an extraction solvent, and fractionating the crude extract with a fraction solvent.

At least one selected from the group consisting of kelp and hwanggi is not limited such as collected, cultivated or marketed, and at least one selected from the group consisting of kelp and hwanggi can be used at any stage during the growing stage Do.

The method for preparing the above extract can be produced by a conventional method for producing a plant extract, specifically a solvent extraction method, a supercritical extraction method, a subcritical extraction method, a high temperature extraction method, a high pressure extraction method or an ultrasonic extraction method, Resin. ≪ / RTI > The adsorption resin may be, for example, XAD or HP-20. The method for preparing the extract may be, for example, a solvent extraction method.

The solvent extraction method may be a heat extraction method, a cold extraction method, a warm-up extraction method, or the like, and a conventional extraction device, an ultrasonic pulverizing extractor, a supercritical extractor, a subcritical extractor or a fractionator may be used.

When one or more kinds of extracts selected from the group consisting of kelp and yellow sea group are prepared by the solvent extraction method, the extraction solvent used in the solvent extraction method may be any one selected from the group consisting of water, an organic solvent, and combinations thereof , The organic solvent may be a polar solvent such as an alcohol having 1 to 5 carbon atoms, a diluted alcohol, ethylacetate or acetone, a nonpolar solvent such as ether, chloroform, benzene, hexane or dichloromethane, or a mixed solvent thereof. The alcohol having 1 to 5 carbon atoms may be methanol, ethanol, propanol, butanol, isopropanol and the like, but is not limited thereto. The alcohol-diluted water may be diluted with water in an amount of 50% (v / v) to 99.9% (v / v) of alcohol.

The extraction solvent of the extract of at least one kind selected from the group consisting of kelp and ylang of the present invention may be at least one selected from the group consisting of water, an alcohol having 1 to 5 carbon atoms, an alcohol diluted water and a mixture thereof, And may be any one selected from the group consisting of water, alcohols having 1 to 4 carbon atoms, and mixtures thereof, and still more preferably water. The extraction process may be performed at, for example, 50 ° C to 250 ° C, or 75 ° C to 200 ° C, or 100 ° C to 150 ° C, but is not limited thereto. The extraction time is not particularly limited, but may be 10 minutes to 24 hours, or 30 minutes to 12 hours, or 1 hour to 5 hours.

The extract may be a fraction prepared by extracting with an extraction solvent or extracting with an extraction solvent and fractionating the extract with a fraction solvent.

The fraction is extracted with an extraction solvent and extracted with any one solvent selected from the group consisting of hexane, methylene chloride, acetone, ethyl acetate, ethyl ether, chloroform, water and mixtures thereof, preferably hexane, methylene chloride and ethyl acetate And the fractionation process is further carried out with at least one solvent selected from the group consisting of Two or more kinds of solvents may be used for the fractionation, and fractions of each extract may be prepared by sequentially using them or by mixing them according to the polarity of the solvent.

The fractionation process may be performed, for example, at 4 ° C to 120 ° C, or 50 ° C to 90 ° C, or 60 ° C to 80 ° C, but is not limited thereto.

The extract or at least one fraction selected from the group consisting of kelp and kelp can be subjected to filtration, concentration or drying to remove the solvent, followed by filtration, concentration and drying . Specifically, the filtration can be performed using a filter paper or a vacuum filter, and the concentration can be reduced by using a vacuum concentrator, for example, a rotary evaporator. The drying can be performed by, for example, freeze drying.

The extract of at least one selected from the group consisting of kelp and hwanggi is extracted and filtered by putting in an extraction container together with an extraction solvent at least one selected from the group consisting of sea tangle and hwanggi, Lt; / RTI > The extracts obtained can be stored in a deep freezer until use.

In addition, at least one extract selected from the group consisting of kelp and hwanggi has been used for a long time as a food material as a natural product isolated from a natural plant or a processed product thereof, and it has been widely used as a food ingredient database (DB) of the Food and Drug Administration It is confirmed that the stability is not a problem.

It has been experimentally confirmed that the extract of at least one selected from the group consisting of kelp and hwanggi has excellent effect of improving thyroid function, and since it has been used for a long time as a food material of food, stability is not a problem, May be used for the improvement or prevention of thyroid disease. From this viewpoint, one or more kinds of extracts selected from the group consisting of kelp and yellow radish can be used as an active ingredient of a food composition for improving or preventing thyroid disease of the extract.

It was confirmed that it is most preferable to add and extract the extraction solvent to the mixture of the extracts mixed at a ratio of 3: 1 (kelp: Hwanggi) on the weight basis. In this respect, the extract may be obtained by adding water to a mixture of sea tangle and horseradish on a weight basis at a ratio of 3: 1 (kelp: ylang-yu) and extracting by hot water extraction.

The composition for improving or preventing thyroid disease is a food composition for improving or preventing thyroid disease, which comprises at least one extract selected from the group consisting of kelp and hwanggi as an active ingredient.

The thyroid disease refers to all diseases that cause thyroid disease and thyroid dysfunction. Non-limiting examples of the thyroid disease include hyperthyroidism, hypothyroidism, thyroiditis, thyroid nodule, thyroid cancer, and the like. The thyroid disease of the present invention is not particularly limited, but it may preferably mean thyroid dysfunction for the purpose of the present invention.

Hypothyroidism refers to all diseases caused by insufficient production of thyroid hormone.

Hypothyroidism is a condition characterized by hypothyroidism, hypothyroidism, pituitary dysfunction, and a lack of thyroid hormone due to intermittent thyroid hormone biosynthetic disorder. The prevalence of hypothyroidism in the elderly is significantly increased, The incidence of subclinical hypothyroidism is 21%. Hypothyroidism is a very slowly progressive disease and is often difficult to recognize. On the other hand, the degree to which the symptoms appear depends on the amount of thyroid hormone in the body, regardless of the cause.

The clinical symptoms of hypothyroidism vary widely depending on the progression of the disease but generally there is a decrease in fatigue and weakness, sensitivity to cold, weight gain, helplessness, helplessness, memory loss, loss of appetite, appear.

Wherein the composition for improving or preventing thyroid disease comprises at least one extract selected from the group consisting of kelp and kelp, as an active ingredient, at least 0.1% by weight of at least one extract selected from the group consisting of kelp and kelp, But it is not limited thereto.

A composition for improving or preventing thyroid disease, which comprises at least one extract selected from the group consisting of kelp and kelp, as an active ingredient, may further comprise at least one extract selected from the group consisting of kelp and hwanggi as an active ingredient, A substance having an effect of improving or preventing a thyroid disease, specifically a substance having at least one kind selected from the group consisting of kelp and hyaluronic acid, or a compound having a known thyroid disease improving or preventing effect, or It may further contain extracts for natural products.

In addition, the food composition for improving or preventing the thyroid disease may be a health functional food for improving or preventing thyroid disease.

The term " food " means a natural product or a processed product containing one or more nutrients, preferably a state of being able to be eaten directly through a certain degree of processing, Beverages, food additives, beverage additives, and the like.

Such foods include, for example, various foods, beverages, gums, tea, vitamin complexes, and health functional foods. In addition, in the present invention, the food may contain special nutritional foods (e.g., crude oil, spirits, infant food, etc.), meat products, fish products, tofu, jelly, noodles (Such as soy sauce, soybean paste, hot pepper paste, mixed sauce), sauces, confectionery (eg snacks), dairy products (eg fermented milk, cheese), other processed foods, kimchi, pickled foods (E.g., fruit, vegetable beverages, two-oil beverages, fermented beverages, etc.), seasonings (e.g., ramen soup, etc.). The food, the health functional food, the beverage, the food additive and the beverage additive can be produced by a usual production method.

The above-mentioned health functional food refers to a food group to which the function of the food is added to a specific purpose by physical, biochemical, and biotechnological techniques, and to control the bio-defense rhythm of the food composition, Means a food which has been designed and manufactured so that the weight control function related to the living body is sufficiently expressed to the living body.

The health functional food may include food-acceptable food supplementary additives, and may further include suitable carriers, excipients and diluents conventionally used in the production of health functional foods.

The drink refers to a generic term for eliminating thirst or drinking to enjoy a taste, and is intended to include a health functional drink. The beverage is not particularly limited as long as it contains at least one extract selected from the group consisting of kelp and ylang as an essential ingredient in an indicated ratio as an active ingredient and is not limited to various ingredients such as various flavors or natural Carbohydrates and the like as additional components.

Examples of such natural carbohydrates include monosaccharides such as disaccharides such as glucose and fructose such as maltose, sucrose and the like and polysaccharides such as dextrins, cyclodextrins and the like, and Xylitol, sorbitol, and erythritol. Natural flavors (tau martin, stevia extract (e.g., rebaudioside A, glycyrrhizin, etc.) and synthetic flavors (saccharin, aspartame, etc.) can be advantageously used as flavors other than those described above The ratio of the natural carbohydrate may be generally about 1 to 20 g, or 5 to 12 g per 100 ml of the food composition of the present invention. In addition, the composition of the present invention may be used for the production of natural fruit juice, fruit juice drink, Can also be added.

In addition to the above, the food composition of the present invention can be used as a flavoring agent such as a variety of nutrients, vitamins, minerals (electrolytes), synthetic flavors and natural flavors, coloring agents and thickening agents (cheese, chocolate etc.), pectic acid and its salts, Salts thereof, organic acids, protective colloid thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, alcohols, carbonating agents used in carbonated drinks, and the like. These components can be used independently or in combination. Although the ratio of such additives is not so important, it may be selected from the range of 0 to 200,000 parts by weight per 100 parts by weight of the extract of at least one kind selected from the group consisting of kelp and hulls of the present invention, but the present invention is not limited thereto.

The health-functional beverage is used to control the bio-defense rhythm of the beverage group or beverage composition to which the added value is imparted so that the function of the beverage functions for a specific purpose by physical, biochemical, biotechnological, or the like, Means a beverage which has been designed so as to sufficiently express the body controlling function related to the living body.

The health functional beverage is not particularly limited as long as it contains one or more extracts selected from the group consisting of kelp and ylang of the present invention as an essential ingredient at the indicated ratio, and may contain various flavors or natural carbohydrates Or the like as an additional component.

Examples of such natural carbohydrates include monosaccharides such as disaccharides such as glucose and fructose such as maltose, sucrose and the like and polysaccharides such as dextrins, cyclodextrins and the like, and xylitol , Sorbitol, and erythritol. Natural flavors (tau martin, stevia extract (e.g., rebaudioside A, glycyrrhizin, etc.) and synthetic flavors (saccharin, aspartame, etc.) can be advantageously used as flavors other than those described above The ratio of the natural carbohydrate is generally about 1 to 20 g, preferably 5 to 12 g per 100 ml of the composition of the present invention.

The present invention also provides a food composition for improving or preventing thyroid disease, which comprises as an active ingredient at least one extract selected from the group consisting of kelp and yellow radish. The active ingredient may be contained in an amount of 0.0001 to 10 wt% , The beverage composition may be included at a ratio of 0.00002 g to 5 g based on 100 ml.

The present invention also relates to a composition for treating or preventing thyroid disease. The composition for treating or preventing thyroid disease may be a pharmaceutical composition for treating or preventing thyroid disease.

The composition for treating or preventing the thyroid disease may include one or more extracts selected from the group consisting of sea tangle and hwanggi as an active ingredient.

The extract of at least one selected from the group consisting of kelp and kelp may be one prepared by a conventional method for producing a plant extract, and examples thereof include at least one kind selected from the group consisting of kelp and yellow kelp, a dried product thereof or a pulverized product thereof , Extracting the juice with an extraction solvent, or extracting the extract with an extraction solvent, and fractionating the crude extract with a fraction solvent.

At least one selected from the group consisting of kelp and hwanggi is not limited such as collected, cultivated or marketed, and at least one selected from the group consisting of kelp and hwanggi can be used at any stage during the growing stage Do.

The method for preparing the above extract can be produced by a conventional method for producing a plant extract, specifically a solvent extraction method, a supercritical extraction method, a subcritical extraction method, a high temperature extraction method, a high pressure extraction method or an ultrasonic extraction method, Resin. ≪ / RTI > The adsorption resin may be, for example, XAD or HP-20. The method for preparing the extract may be, for example, a solvent extraction method.

The solvent extraction method may be a heat extraction method, a cold extraction method, a warm-up extraction method, or the like, and a conventional extraction device, an ultrasonic pulverizing extractor, a supercritical extractor, a subcritical extractor or a fractionator may be used.

When one or more kinds of extracts selected from the group consisting of kelp and yellow sea group are prepared by the solvent extraction method, the extraction solvent used in the solvent extraction method may be any one selected from the group consisting of water, an organic solvent, and combinations thereof , The organic solvent may be a polar solvent such as an alcohol having 1 to 5 carbon atoms, a diluted alcohol, ethylacetate or acetone, a nonpolar solvent such as ether, chloroform, benzene, hexane or dichloromethane, or a mixed solvent thereof. The alcohol having 1 to 5 carbon atoms may be methanol, ethanol, propanol, butanol, isopropanol and the like, but is not limited thereto. The alcohol-diluted water may be diluted with water in an amount of 50% (v / v) to 99.9% (v / v) of alcohol.

The extraction solvent of the extract of at least one kind selected from the group consisting of kelp and ylang of the present invention may be at least one selected from the group consisting of water, an alcohol having 1 to 5 carbon atoms, an alcohol diluted water and a mixture thereof, And may be any one selected from the group consisting of water, alcohols having 1 to 4 carbon atoms, and mixtures thereof, and still more preferably water. The extraction process may be performed at, for example, 50 ° C to 250 ° C, or 75 ° C to 200 ° C, or 100 ° C to 150 ° C, but is not limited thereto. The extraction time is not particularly limited, but may be 10 minutes to 24 hours, or 30 minutes to 12 hours, or 1 hour to 5 hours.

The extract may be a fraction prepared by extracting with an extraction solvent or extracting with an extraction solvent and fractionating the extract with a fraction solvent.

The fraction is extracted with an extraction solvent and extracted with any one solvent selected from the group consisting of hexane, methylene chloride, acetone, ethyl acetate, ethyl ether, chloroform, water and mixtures thereof, preferably hexane, methylene chloride and ethyl acetate And the fractionation process is further carried out with at least one solvent selected from the group consisting of Two or more kinds of solvents may be used for the fractionation, and fractions of each extract may be prepared by sequentially using them or by mixing them according to the polarity of the solvent.

The fractionation process may be performed, for example, at 4 ° C to 120 ° C, or 50 ° C to 90 ° C, or 60 ° C to 80 ° C, but is not limited thereto.

The extract or at least one fraction selected from the group consisting of kelp and kelp can be subjected to filtration, concentration or drying to remove the solvent, followed by filtration, concentration and drying . Specifically, the filtration can be performed using a filter paper or a vacuum filter, and the concentration can be reduced by using a vacuum concentrator, for example, a rotary evaporator. The drying can be performed by, for example, freeze drying.

The extract of at least one selected from the group consisting of kelp and hwanggi is extracted and filtered by putting in an extraction container together with an extraction solvent at least one selected from the group consisting of sea tangle and hwanggi, Lt; / RTI > The extracts obtained can be stored in a deep freezer until use.

It has been experimentally confirmed that the extract of at least one selected from the group consisting of kelp and hwanggi has excellent effect of improving thyroid function, and since it has been used for a long time as a food material of food, stability is not a problem, May be used for the treatment or prevention of thyroid disease. From this viewpoint, one or more kinds of extracts selected from the group consisting of kelp and yellow radish can be used as an active ingredient of a pharmaceutical composition or pharmaceutical composition for treating or preventing thyroid disease of the extract.

It was confirmed that it is most preferable to add and extract the extraction solvent to the mixture of the extracts mixed at a ratio of 3: 1 (kelp: Hwanggi) on the weight basis. In this respect, the extract may be obtained by adding water to a mixture of sea tangle and horseradish on a weight basis at a ratio of 3: 1 (kelp: ylang-yu) and extracting by hot water extraction.

The thyroid disease refers to all diseases that cause thyroid disease and thyroid dysfunction. Non-limiting examples of the thyroid disease include hyperthyroidism, hypothyroidism, thyroiditis, thyroid nodule, thyroid cancer, and the like. The thyroid disease of the present invention is not particularly limited, but it may preferably mean thyroid dysfunction for the purpose of the present invention.

Hypothyroidism refers to all diseases caused by insufficient production of thyroid hormone.

Hypothyroidism is a condition characterized by hypothyroidism, hypothyroidism, pituitary dysfunction, and a lack of thyroid hormone due to intermittent thyroid hormone biosynthetic disorder. The prevalence of hypothyroidism in the elderly is significantly increased, The incidence of subclinical hypothyroidism is 21%. Hypothyroidism is a very slowly progressive disease and is often difficult to recognize. On the other hand, the degree to which the symptoms appear depends on the amount of thyroid hormone in the body, regardless of the cause.

The clinical symptoms of hypothyroidism vary widely depending on the degree of disease progression but are generally associated with fatigue and weakness, sensitivity to cold, weight gain, helplessness, helplessness, memory loss, loss of appetite, deficiency, muscle pain, arthralgia, .

A composition for treating or preventing a thyroid disease, wherein the composition comprises at least one extract selected from the group consisting of kelp and kelp, as an active ingredient, can be directly applied to animals including humans. The animal is a group of organisms corresponding to plants. It mainly consumes organic matter as nutrients, and differentiates digestive organs, excretory or respiratory organs. Preferably, it is a mammal, more preferably a human.

The composition may be used alone in a composition for the treatment or prevention of thyroid disease, wherein the composition contains at least one extract selected from the group consisting of kelp and hyaluronic acid as an active ingredient, and further includes a pharmacologically acceptable carrier, excipient, diluent or sub ingredient . More particularly, when a composition for treating or preventing thyroid disease comprising at least one extract selected from the group consisting of kelp and yellow radish as an active ingredient is used as a medicine or used for medicinal or pharmaceutical use, May be mixed with a pharmaceutically acceptable carrier or excipient according to a conventional method, or diluted with a diluent.

In addition, a composition for treating or preventing a thyroid disease, which comprises at least one extract selected from the group consisting of kelp and yellow radish as an active ingredient, may further comprise at least one selected from the group consisting of nutrients, vitamins, electrolytes, flavors, colorants, An organic acid, a protective colloid thickener, a pH adjusting agent, a stabilizer, a preservative, a glycerin, an alcohol, a carbonating agent used in a carbonated drink, and the like.

The carrier, excipient or diluent may be selected from lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acicia gum, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methylcellulose, microcrystalline In the group consisting of celluloses, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil, dextrin, calcium carbonate, propylene glycol, liquid paraffin, But the present invention is not limited thereto. Any conventional carrier, excipient or diluent may be used. The components can be added to the active ingredient, i.e., tangle fermentation, either independently or in combination.

A composition for treating or preventing thyroid disease, which comprises at least one extract selected from the group consisting of kelp and yellow radish as an active ingredient, may contain 0.001% by weight to 99.9% by weight, preferably 0.1% by weight, To 99% by weight, more preferably 1% by weight to 50% by weight. However, the present invention is not limited thereto, and one or more extracts selected from the group consisting of kelp The content of the active ingredient contained in the composition for treating or preventing thyroid disease, which is included as a component, can be appropriately adjusted in a pharmaceutically effective amount or a preferable amount. In addition, the content of the additional ingredient may be added in the range of 0.1% by weight to 20% by weight based on the total weight of the composition for treating or preventing thyroid disease, but is not limited thereto.

In the present invention, pharmacologically acceptable means physiologically acceptable and when administered to an animal, preferably a human, does not normally cause an allergic reaction such as a gastrointestinal disorder, dizziness or a similar reaction. The pharmaceutically effective amount may be appropriately changed depending on the disease and its severity, the age, body weight, health condition, sex, administration route and treatment period of the patient.

When the composition for treating or preventing a thyroid disease comprising an extract of at least one selected from the group consisting of kelp and yellow radish is used as an active ingredient, conventional fillers, extenders, binders, disintegrants, surfactants, , A lubricant, a wetting agent, a flavoring agent, an emulsifying agent, or an antiseptic, and may be used either orally or parenterally.

Particularly, solid preparations for oral administration include tablets, pills, powders, granules, capsules and the like. These solid preparations can be prepared by adding to the above active ingredient, i.e., ternary fermentation product, at least one excipient such as starch, calcium carbonate calcium carbonate, sucrose or lactose, and gelatin. In addition to simple excipients, lubricants such as magnesium stearate and talc may also be used. Liquid preparations for oral use include suspensions, solutions, emulsions, and syrups. In addition to water and liquid paraffin, which are commonly used simple diluents, various excipients such as wetting agents, sweetening agents, have.

In addition, the composition for treating or preventing thyroid disease, which comprises the extract of one or more selected from the group consisting of kelp and yellow fever of the present invention as an active ingredient, may be in a form suitable for the method of use, Can be formulated employing methods known in the art to provide rapid, sustained or delayed release of the active ingredient. Examples of the specific formulations include granules, powders, syrups, liquids, suspensions, tablets, injections, main tablets, cataplasma, capsules, soft or hard gelatin capsules and the like.

Further, a composition for treating or preventing thyroid disease, which comprises an extract of at least one member selected from the group consisting of kelp and erysipelas of the present invention as an active ingredient, may be prepared using a suitable method known in the art or by using Remington's Pharmaceutical Science (Recent edition), Mack Publishing Company, Easton PA).

The dosage of the composition for treating or preventing thyroid disease, which comprises at least one extract selected from the group consisting of kelp and hyaluronic acid according to the present invention, as an active ingredient, can be appropriately determined depending on the administration method, age, sex and weight of the recipient, May be appropriately selected by those skilled in the art. For example, the composition for treating or preventing a thyroid disease, which is included as an active ingredient of the present invention, may contain 0.00001 mg / kg to 10,000 mg / kg, more preferably 0.001 mg / kg to 5,000 mg, / kg. < / RTI > The administration may be carried out once a day or divided into several times. The dose is not intended to limit the scope of the invention in any way.

In addition, the composition for treating or preventing thyroid disease, wherein the composition comprises at least one extract selected from the group consisting of kelp and hyaluronic acid as an active ingredient, can be used for the treatment or prevention of thyroid diseases, specifically hypothyroidism, Compound or natural product, and may be included in an amount of 5 to 200 parts by weight based on 100 parts by weight of the active ingredient.

The present inventive extract of at least one member selected from the group consisting of kelp and hwanggi has been found to be effective in improving thyroid function in the experimental results. Therefore, the hormone replacement therapy (hormone replacement therapy) to prevent, alleviate or treat hypothyroidism and various symptoms thereof replacement therapy (HRT), and unlike conventional therapies for thyroid disease, safety is not a problem, and at least one selected from the group consisting of kelp and hwanggi has long been used as herbal medicine or food Since it is a safe substance with few side effects, it has an excellent effect as compared with a therapeutic agent for thyroid disease.

FIG. 1 is a graph showing changes in body weight of an experimental animal administered with kelp and hot water extracts according to an embodiment of the present invention. In FIG. 1, the abscissa indicates the elapsed time and date of the experiment and the ordinate indicates the degree of change in body weight .
FIG. 2 is a photograph of a thyroid of an experimental animal administered with a hot-water extract of each of kelp and hwanggi according to an embodiment of the present invention. The left side indicates thyroid before treatment with antithyroid agent (PTU), the right side indicates antithyroid agent B means the negative control treated with anti-thyroid agent, C means the positive control (LT4), D means the thyroid gland of the present invention (Body weight) of 400 mg / kg (body weight), and E represents the experimental group of 200 mg / kg (body weigh) of the mixture of sea tangle and hot water extract of the present invention, F means an experimental group in which 100 mg / kg (body weigh) of the mixture of the sea tangle and hwanggi hot water extract of the present invention was administered. In the above photograph, the scale bar is 5 mm.
FIG. 3 is a photograph of testis of an experimental animal to which hot-water extract of each of kelp and hwanggi was administered according to an embodiment of the present invention, wherein A means a control group not treated with any sample, B indicates a negative control group treated with anti- (C) represents a positive control (LT4), D represents an experimental group administered with 400 mg / kg body weigh of a mixture of sea tangle and hot water extract of the present invention, E represents kelp and Means a group of 200 mg / kg (body weigh) administration of a mixture of Hwanggi and hot water extracts, and F means an experimental group of 100 mg / kg (body weigh) of a mixture of sea tangle and hot water extract of the present invention. In the above photograph, the scale bar is 8.4 mm.
FIG. 4 is a graph showing changes in AST and ALT contents in serum of experimental animals to which hot-water extracts of kelp and hwanggi, respectively, according to an embodiment of the present invention are administered, wherein the horizontal axis indicates the type of experiment group, ALT content, Controls means the control group, and LT4 means the positive control group.
FIG. 5 is a histopathological photograph of the thyroid gland of an experimental animal to which hot-water extract of each of kelp and hwanggi was administered according to an embodiment of the present invention, wherein A represents a control group in which no sample is treated, B represents an anti- (C) represents a positive control (LT4), D represents an experimental group administered with 400 mg / kg body weigh of a mixture of the sea tangle and hot water extract of the present invention, and E represents a negative control group F means a test group administered with 100 mg / kg body weight of a mixture of sea tangle and hot water extract of the present invention at a dose of 200 mg / kg body weigh of the present invention, . In the above photograph, the scale bar is 480 μm.
FIG. 6 is a histopathological photograph of hepatic histopathology of experimental animals administered with hot water extracts of each of kelp and hwanggi according to an embodiment of the present invention, wherein A represents a control group in which no sample is treated, B represents an anti-thyroid agent (C) represents a positive control (LT4), D represents an experimental group administered with 400 mg / kg body weigh of a mixture of sea tangle and hot water extract of the present invention, F means the test group in which 100 mg / kg body weigh of the mixture of sea tangle and hot water extract of the present invention was administered. it means.
FIG. 7 is a histopathological photograph of the testis of an experimental animal administered with hot water extracts of each of kelp and hwanggi according to an embodiment of the present invention, wherein A means a control group in which no sample is treated, (C) represents a positive control (LT4), D represents an experimental group administered with 400 mg / kg body weigh of a mixture of the sea tangle and hot water extract of the present invention, and E represents a negative control group F means a test group administered with 100 mg / kg body weight of a mixture of sea tangle and hot water extract of the present invention at a dose of 200 mg / kg body weigh of the present invention, .
FIG. 8 is a histopathological photograph of epididymis of experimental animals to which hot-water extract of each of kelp and hwanggi was administered according to an embodiment of the present invention, wherein A denotes a control group in which no sample is treated, B denotes an anti-thyroid (C) represents a positive control (LT4), D represents an experimental group administered with 400 mg / kg body weigh of a mixture of the sea tangle and hot water extract of the present invention, and E represents a negative control group F means a test group administered with 100 mg / kg body weight of a mixture of sea tangle and hot water extract of the present invention at a dose of 200 mg / kg body weigh of the present invention, .
9 is a histopathological photograph of a prostate gland of an experimental animal to which hot water extracts of kelp and hwanggi, respectively, according to an embodiment of the present invention are administered, wherein A represents a control group in which no sample is treated, B represents an anti thyroid (C) represents a positive control (LT4), D represents an experimental group administered with 400 mg / kg body weigh of a mixture of the sea tangle and hot water extract of the present invention, and E represents a negative control group F means a test group administered with 100 mg / kg body weight of a mixture of sea tangle and hot water extract of the present invention at a dose of 200 mg / kg body weigh of the present invention, .

Hereinafter, embodiments of the present invention will be described in detail so that those skilled in the art can easily carry out the present invention. The present invention may, however, be embodied in many different forms and should not be construed as limited to the embodiments set forth herein.

All data in the examples of the present invention are presented as mean + -SEM from five or more independent experiments. Statistical significance of differences between groups was calculated using the Student's two tailed t-test (*, P <0.05; **, P <0.01).

< Example  1. Licorice and Hwanggi  Preparation of Extract>

Liquorice and Hwanggi extracts were prepared as follows.

Specifically, after purchasing kelp and hwanggi purchased from domestic or cultivated in Korea, they were washed three times from the water to remove impurities, and each of the kelp and hwanggi was incubated for 24 hours Followed by lyophilization, followed by pulverization with a pulverizer to prepare a pulverized material.

Each of the 300 g of Kelp and 100 g of Crude Grass was added with 1 L of water and homogenized. The mixture was subjected to hot water extraction at 120 ° C. for 120 minutes, and each 80 mesh filter cloth was tightened with a filter, Press, Koreafilter, KFP-600MM-25-16-S, Korea). The extracts of each of the concentrated kelp and hwanggi were lyophilized at -20 ° C for 72 hours to prepare a crude powdery extract. The extracts were dissolved in distilled water to prepare samples of licorice, yanggi, and yanggi extracts. The samples of licorice, yanggi and yanggi extracts were stored at -20 ° C until use. The extracts were dried and stored at -20 ° C until use.

< Example  2. Licorice and Hwanggi  Identification of thyroid improving effect of extracts>

2-1. Experimental Method

In this study, oral administration of 10 mg / kg PTU (Propylthiouacil, 6-n-propyl-2-thiouacil) once a day for 28 days resulted in hypothyroidism, 200 and 100 mg / kg were orally administered once a day for 42 days from 2 weeks before the start of PTU administration and the body weight, thyroid, liver, prostate, epididymal and testicular weight, blood thyroid hormone (TSH, T3 and T4) Serum lipid peroxidation (H2O2, SOD and CAT), serum AST and alanine levels, serum lipid peroxidation, total cholesterol (TC), triglyceride (TG), LDL and HDL levels, testosterone, DHT and FSH levels, Changes in aminotransferase (ALT) content were observed with histopathological changes of thyroid, liver, testis, prostate, and epididymis. The dose of LT4 (Levothyroxine) used in this study was 0.5 mg / kg (ip) administered based on the results of previous experiments on PTU-induced hypothyroidism in rats. Normal medium and PTU control group were separately prepared.

All three doses of AL mix were dissolved in sterile distilled water at an appropriate dose and orally administered at a dose of 5 ml / kg, the usual oral dose of the rat. The LT4 and PTU were dissolved in physiological saline, And repeated dose of 1 ml / kg was administered intraperitoneally and subcutaneously, respectively. In the present experiment, the results were compared with that of LT4 0.5 mg / kg (intraperitoneally for 28 days once daily from PTU administration).

A total of 66 healthy male SD rats were obtained from SPF / VAF Sprague-Dawley, Crl: CD [SD] rats (6 week old male, OrientBio, Seungnam, Korea) for 7 days, 292.58 ± 5.08 g, and 264 to 318 g) were used for the experiments.

All animals were fasted for 18 hours or more at the beginning of the treatment and at the end of the last autopsy (negative water was also freely supplied during this period), and individuals were identified with picric acid. This animal experiment was conducted with the prior approval of the Animal Experimental Ethics Committee of Silla University (Busan, Korea).

Experimental animals were experimented with a total of 6 groups of 8 animals per group as shown in Table 1 below. (PTU 10 mg / kg subcutaneously and sterilized distilled water oral administration group), LT4 group (PTU 10 mg / kg subcutaneously and LT4 0.5 mg / kg peritoneal administration group), the normal medium control group (physiological saline subcutaneously and sterilized distilled water administration group) ) AL mix 400 group (subcutaneous PTU 10 mg / kg subcutaneous and AL mix 400 mg / kg group), AL mix 200 group (subcutaneous PTU 10 mg / kg subcutaneous and AL mix 200 mg / PTU 10 mg / kg subcutaneously and AL mix 100 mg / kg orally administered group).

The hypothyroidism was induced by dissolving PTU in physiological saline solution at a concentration of 10 mg / ml in a laboratory animal and adding 1 ml of 1 ml / kg (10 mg / kg) Subcutaneous administration to the dorsal skin using a syringe resulted in hypothyroidism. On the other hand, in the normal medium control group, only the same dose of physiological saline was administered in the same manner and for the same period of time in order to apply the same administration stress.

(TSH, T3 and T4) levels, testosterone, DHT and FSH levels, blood lipid levels (TC, HDL, LDL and LDH), body weight, thyroid gland, liver, prostate, epididymis and testicular weight, and serum thyroid hormone TG) content, liver and testis antioxidant defense system (lipid peroxidation, H2O2, SOD and CAT), changes in blood AST and ALT contents, thyroid (total thyroid thickness and mean thyroid follicle diameter), liver (Mean diameter of the canaliculus and the proportion of canals of stage I to II containing mature sperm in the catheter), the prostate (the average thickness of the prostate duct epithelium and the ratio of the atrophic prostate duct), and the epididymis Thickness and the number of spermatozoa).

2-2. Experiment result

First, changes in body weight and weight gain were confirmed and are shown in Table 2 and Fig.

As shown in Table 2 and FIG. 1, a significant (p <0.01) decrease in body weight was observed in the PTU control group compared to the normal medium control group after 2 weeks of PTU administration (Day 28) (P <0.01) were significantly lower than those of normal control group. On the other hand, in the LT4-treated group, a significant increase (p <0.01) in body weight was observed from the third week after PTU administration to the PTU control group, and the body weight gain during the PTU administration period and the pre- 0.01). In the AL mix 400 and 200 mg / kg group, the weight gain was significantly (p <0.01) higher than that of the PTU control group. <0.01), and the increase in body weight during the PTU administration period and the whole period of the experiment were respectively recognized. On the other hand, in the AL mix 100 mg / kg administration group, significant changes in body weight and body weight were not observed compared with the PTU control group.

In addition, the body weight gain of the PTU control group was 0.56% higher than that of the normal control group during the 2 weeks of the experiment, and in the LT mixer 0.5 mg / kg, AL mix 400, 200 and 100 mg / Respectively, compared with those of the control group.

In addition, the body weight gain during 4 weeks of PTU administration was -132.43% higher in the PTU control group than in the control group. However, in the LT 4 0.5 mg / kg, AL mix 400, 200 and 100 mg / Respectively, compared with those of the control group, 283.69, 245.23, 197.79 and 13.82%, respectively.

The body weight gain of PTU control group was -46.06% compared with that of normal control group during the 6 weeks before the experiment. However, in the LT 4 0.5 mg / kg, AL mix 400, 200 and 100 mg / 52.93, 38.78 and 1.08%, respectively.

Changes in the weight of the thyroid gland were also confirmed and are shown in Fig. 2 and Table 3 below.

As shown in FIG. 2 and Table 3, in the PTU control group, a significant thyroid enlargement was observed compared with the normal medium control group, and an increase in absolute and relative thyroid weight was recognized (p <0.01) In the AL mix 400 and 200 mg / kg administration groups, the absolute and relative thyroid weights were significantly reduced (p <0.01), respectively, as compared to the PTU control group. On the other hand, in the AL mix 100 mg / kg group, no significant change in relative thyroid gland relative to the PTU control group was observed.

The mean absolute thyroid weight was 409.59% in the PTU control group compared with the normal control group. However, in the LT 4 0.5 mg / kg, AL mix 400, 200 and 100 mg / kg administration groups, -50.54, -29.30 and -4.84%, respectively.

The relative weight of the thyroid gland was 524.40% in the PTU control group compared to the control group of the normal medium, but -84.92, -55.99, -35.99 and -5.69%, respectively.

Changes in the weight of various organs including the liver were confirmed and shown in Fig. 3 and Table 4, respectively.

As shown in FIG. 3 and Table 4, in the PTU control group, the absolute and relative liver weights were decreased (p <0.01) compared to the normal medium control group. However, LT4 0.5 mg / kg, AL mix 400 and 200 mg / (p < 0.01 or p < 0.05), respectively, as compared with the PTU control group. On the other hand, in the AL mix 100 mg / kg administration group, no significant change in relative liver weight or absolute weight was observed compared with the PTU control group.

The absolute liver weight of the PTU control group was -37.96% as compared with the normal control group. However, in the LT 4 0.5 mg / kg, AL mix 400, 200 and 100 mg / kg administration groups, 29.94, 21.19 and 4.08%, respectively.

The relative weight of the liver was -24.24% in the PTU control group compared with the normal medium control group. However, in the LT 4 0.5 mg / kg, AL mix 400, 200 and 100 mg / kg administration groups, 14.90, 9.93 and 3.40%, respectively.

Further, changes in the weights of the high-grade, epididymal and prostate gland were confirmed, and are shown in Fig. 3 and Table 4 below.

As shown in FIG. 3 and Table 4, remarkable testicular atrophy was recognized in the PTU control group compared to the normal medium control group, and a significant (p < 0.01) In the mg / kg group, the absolute and relative testicle weights were significantly increased (p <0.01) compared to the PTU control group, respectively. On the other hand, in test group with 0.5 mg / kg of LT4, testicular absolute and relative weight decreased significantly (p <0.01) compared to PTU control group. In the AL mix 100 mg / kg administration group, significant testicular weight change Was not recognized.

The absolute weight of testes was -29.64% in the PTU control group compared to the normal medium control group. However, in the LT 4 0.5 mg / kg, AL mix 400, 200 and 100 mg / , 27.17, 23.32 and 2.56%, respectively.

The relative weight of the testes was -13.85% in the PTU control group compared to the normal medium control group, but -38.44% in the LT4 0.5 mg / kg, AL mix 400, 200 and 100 mg / , 12.19, 11.72 and 1.69%, respectively.

In addition, as shown in FIG. 3 and Table 4, in the PTU control group, significant epididymal atrophy was recognized as compared with the normal medium control group, and a significant (p < 0.01) And 200 mg / kg were significantly (p <0.01) higher than those of the PTU control group, respectively. On the other hand, in the LT 4 0.5 mg / kg administration group, the epididymal absolute and relative weight decreased significantly (p <0.01) compared with the PTU control group, and in the AL mix 100 mg / kg administration group, No change was recognized.

In addition, the epididymal absolute weight showed -44.59% change in the PTU control group compared with the normal medium control group. However, in the LT 4 0.5 mg / kg, AL mix 400, 200 and 100 mg / , 44.29, 34.38 and 2.11%, respectively.

In addition, the epididymal relative weights were -32.08% in the PTU control group compared to the normal medium control group, but -30.32% in the LT4 0.5 mg / kg, AL mix 400, 200 and 100 mg / , 26.88, 21.75 and 1.00%, respectively.

As shown in FIG. 3 and Table 4, the decrease in absolute and relative prostate weights was significant (p <0.01) in the PTU control group as compared with the normal medium control group. However, in the AL mix 400 administration group, p <0.01), and the AL mix 200 mg / kg group showed no significant difference, but showed a significant increase in prostate relative weight and absolute weight compared to the medium control group. On the other hand, prostate absolute and relative weight reduction was significantly (p <0.01) lower in the LT4 0.5 mg / kg group than in the PTU control group. In the AL mix 100 mg / kg group, significant prostate weight change Was not recognized.

The absolute weight of the prostate was -45.72% in the PTU control group compared with the normal control group. However, in the LT 4 0.5 mg / kg, AL mix 400, 200 and 100 mg / kg administration groups, -26.25 and 34.65 , 27.27 and 4.91%, respectively.

The prostate relative weight showed a change of -33.58% in the PTU control group compared to the normal medium control group, but -36.30 and 18.80% in the LT4 0.5 mg / kg, AL mix 400, 200 and 100 mg / , 15.20 and 3.89%, respectively.

In addition, changes in blood thyroid hormone contents were confirmed and are shown in Table 5 below.

As shown in Table 5, in the PTU control group, the increase in the TSH content in the serum was significant (p <0.01) as compared with that in the normal medium control group, but the AL mix 400 and 200 mg / kg group (P <0.01), respectively, as compared with the PTU control group. In addition, in the LT4 treated group, there was a significant decrease (p <0.01) in TSH content and T4 content compared to the PTU control group, but no significant change in the T3 content in the blood was observed. On the other hand, no significant change in TSH, T3 and T4 levels was observed in the AL mix 100 mg / kg group compared with the PTU control group.

Serum TSH content of the PTU control group was 404.16% higher than that of the normal control group. However, in the LT 4 0.5 mg / kg, AL mix 400, 200 and 100 mg / kg administration groups, -83.69 and -43.69 , -37.32 and -2.37%, respectively.

The T3 content of the PTU group was -76.35% higher than that of the normal control group. However, in the LT 4 0.5 mg / kg, AL mix 400, 200 and 100 mg / kg groups, the PTU control group showed -8.43 and 103.62 , 67.84 and 1.01%, respectively.

The T4 content of the PTU group was -88.01% higher than that of the normal control group. However, in the LT 4 0.5 mg / kg, AL mix 400, 200 and 100 mg / kg groups, the PTU control group showed 834.76, 277.25, 126.70 and 4.42%, respectively.

In addition, changes in liver antioxidant defense system were confirmed and are shown in Table 6 below.

As shown in Table 6, in the PTU control group, a slight decrease in the lipid peroxidation (MDA content), which was not significant compared to the normal control group, was recognized, but the increase in the H2O2 and SOD activity between the significant (p <0.01) (p < 0.01). The increase in CAT activity (p <0.01) in LT4 0.5 mg / kg, AL mix 400 and 200 mg / kg administration groups, respectively, as compared with the PTU control group, was recognized with a decrease in H2O2 content and SOD activity. On the other hand, in the AL mix 100 mg / kg administration group, significant hepatic antioxidant defense system - lipid peroxidation, H2O2 content, CAT and SOD activity were not changed compared to the PTU control group.

The lipid peroxidation, ie, MDA content, in the liver tissue was -5.31% higher in the PTU control group than in the normal medium control group. However, in the LT 4 0.5 mg / kg, AL mix 400, 200 and 100 mg / , Respectively, which were 8.41, 4.85, 1.29 and 9.16%, respectively.

The H2O2 content in the liver tissues was 169.56% as compared to the normal medium control group. However, in the LT 4 0.5 mg / kg, AL mix 400, 200 and 100 mg / kg administration groups, the content of H2O2 was -64.90, -36.97, -28.32 and -4.95%, respectively.

The SOD activity in the liver tissue was 122.38% higher than that of the normal medium control group. However, in the LT 4 0.5 mg / kg, AL mix 400, 200 and 100 mg / kg administration groups, -40.58, -31.26 and -5.67%, respectively.

The CAT activity in the liver was -72.55% in the PTU control group compared with the normal control group. However, in the LT 4 0.5 mg / kg, AL mix 400, 200 and 100 mg / kg administration groups, 117.18, 72.32 and 5.03%, respectively.

In addition, changes in the AST and ALT contents in the serum were confirmed and shown in FIG.

As shown in FIG. 4, in the PTU control group, the AST content in the serum was significantly increased (p <0.01) as compared with the normal medium control group. However, the increase of the AST content by the PTU administration was 0.5 mg / kg of LT4 mix 400 and 200 mg / kg, respectively (p < 0.01). On the other hand, in the AL mix 100 mg / kg group, there was no significant change in the AST and ALT contents in the blood compared to the PTU control group. In the PTU control group, only a slight increase in the ALT content was observed in comparison with the normal medium control group. The changes in serum ALT levels were also not observed in the LT4 0.5 mg / kg, AL mix 400 and 200 mg / kg groups.

The AST content of serum in the PTU control group was 141.27% compared with that of the normal medium control group. However, in the LT 4 0.5 mg / kg, AL mix 400, 200 and 100 mg / 36.23, -28.21 and -8.81%, respectively.

The ALT content in the serum was 11.88% in the PTU control group compared with the normal control group. However, in the LT 4 0.5 mg / kg and AL mix 400, 200 and 100 mg / kg administration groups, -8.38 and 1.12 , -0.28 and 3.07%, respectively.

The change in the lipid content in the serum was confirmed and is shown in Table 7.

As shown in Table 7, in the PTU control group, there was a significant (p <0.01) decrease in serum HDL and serum TG levels compared to the normal medium control group (p <0.01) , AL mix 400 and 200 mg / kg administration group, respectively (p <0.01 or p <0.05), compared with the PTU control group. On the other hand, in the AL mix 100 mg / kg group, there was no significant change in blood lipids - TC, LDL, HDL and TG contents compared with the PTU control group, and significant changes in blood TC and LDL levels in the PTU control group . Changes in serum TC and LDL levels were not observed in the LT4 0.5 mg / kg, AL mix 400 and 200 mg / kg groups compared to the PTU control group.

The TC content of serum was 3.23% in PTU control group compared with that of normal control group. However, in LT 4 0.5 mg / kg, AL mix 400, 200 and 100 mg / , -2.85 and -1.86%, respectively.

The LDL content in the serum was 0.38% compared with the PTU control group, while the PTU control group showed a -0.38% change compared to the normal control group. In the LT 4 0.5 mg / kg and AL mix 400, 200 and 100 mg / , 1.21 and 0.83%, respectively.

Serum HDL content was 193.28% in the PTU control group compared with the normal control group. However, in the LT 4 0.5 mg / kg, AL mix 400, 200 and 100 mg / kg administration groups, 45.29, -32.28 and -2.91%, respectively.

The TG content in serum was -62.39% as compared with the normal medium control group in the PTU control group, but 158.69 and 87.84% in the LT 4 0.5 mg / kg and AL mix 400, 200 and 100 mg / , 53.99 and 3.88%, respectively.

In addition, changes in the serum sex hormone content were confirmed and are shown in Table 8.

As shown in Table 8, in the PTU control group, the increase in the FSH content in the serum was significant (p <0.01) as compared with that in the normal medium control group, while the testosterone and DHT contents were decreased. However, AL mix 400 and 200 mg / (P <0.01 or p <0.05) in the serum compared to the PTU control group, with a decrease in the FSH content of the serum with an increase in testosterone and DHT content. In contrast, in the LT4 group, the FSH content and the DHT and testosterone content were significantly decreased (p <0.01) compared to the PTU control group. In the AL mix 100 mg / kg group, , testosterone and DTH contents were not observed.

Serum testosterone content was -49.07% in the PTU control group compared to the normal medium control group, but -24.96 and 36.12 times in the LT 4 0.5 mg / kg, AL mix 400, 200 and 100 mg / , 23.01 and 4.29%, respectively.

The levels of DHT in the PTU-treated group were -47.56% compared with the normal control group. However, in the LT 4 0.5 mg / kg, AL mix 400, 200 and 100 mg / , 36.31 and 4.77%, respectively.

Serum FSH content was 109.49% in the PTU control group compared with the normal control group. However, in the LT 4 0.5 mg / kg and AL mix 400, 200 and 100 mg / kg administration groups, the PTU control group showed 36.60, -26.04, -19.50 and -5.60%, respectively.

In addition, changes in testicular antioxidant defense system were confirmed and shown in Table 9.

As shown in Table 9, a slight decrease in lipid peroxidation was observed in the PTU control group as compared with the normal medium control group, but a significant (p <0.01) increase in the H2O2 content was significant (p <0.01 ) Reduction. AL mix 400 and 200 mg / kg, respectively, with a significant (p <0.01) increase in SOD and CAT activity compared to PTU control, with a significant (p <0.01) decrease in H2O2 content. On the other hand, in the LT4-treated group, CAT and SOD activities were significantly decreased (p <0.01) compared with the PTU-treated group, and the H2O2 content was increased in the testis. In the AL mix 100 mg / kg group, Changes in lipid peroxidation, H2O2 content, CAT and SOD activity were not observed.

The MDA content in the testis tissue was -12.16% as compared to the normal medium control group in the PTU control group. However, in the LT 4 0.5 mg / kg, AL mix 400, 200 and 100 mg / 11.97, 10.17 and 1.39%, respectively.

The H2O2 content in the testis tissue was 206.84% as compared to the normal medium control group in the PTU control group but 39.62% in the LT4 0.5 mg / kg, AL mix 400, 200 and 100 mg / 37.56, -27.10 and -7.20%, respectively.

SOD activity in the testis tissue was -74.88% as compared to the normal medium control group in the PTU control group, but -35.29% in the LT4 0.5 mg / kg and AL mix 400, 200 and 100 mg / , 119.61, 79.41 and 4.90%, respectively.

The CAT activity in the testis tissue was -76.19% as compared with the normal medium control group in the PTU control group, but -37.78% in the LT4 0.5 mg / kg, AL mix 400, 200 and 100 mg / , 130.00, 68.89 and 5.56%, respectively.

In addition, histopathological changes of the thyroid gland were confirmed and are shown in Table 10 and Fig.

As shown in Table 10 and FIG. 5, in the PTU control group, the enlargement of the thyroid follicular cells by the enlargement of the thyroid follicular cells was recognized with the decrease of the follicular diameter and the follicular colloid material, (p <0.01) increased with a significant (p <0.01) decrease in mean thyroid follicle diameter. On the other hand, the enlargement and hypertrophy of thyroid tissue by PTU administration was significantly inhibited by LT4 0.5 mg / kg, AL mix 400 and 200 mg / kg. (P <0.01 or p <0.05) in the LT4 0.5 mg / kg, AL mix 400 and 200 mg / kg administration groups, respectively, as compared with the PTU control group, indicating a decrease in the total thyroid thickness and an increase in the mean thyroid follicle diameter. On the other hand, in the AL mix 100 mg / kg group, there was no significant change in thyroid gland histopathologic change - total thyroid thickness and mean thyroid follicle diameter compared with the PTU control group.

The total thickness of the thyroid gland was 69.55% in the PTU control group compared with the normal medium control group. However, in the LT 4 0.5 mg / kg, AL mix 400, 200 and 100 mg / kg administration groups, -43.31 and -28.77 , -19.52 and -2.40%, respectively.

The average thyroid follicle diameter was -66.81% in the PTU control group compared with the normal medium control group. However, in the LT 4 0.5 mg / kg, AL mix 400, 200 and 100 mg / kg administration groups, 142.13 and 80.56 , 50.30 and 5.08%, respectively.

In addition, histopathological changes in the liver were confirmed and are shown in Table 10 and FIG.

As shown in Table 10 and FIG. 6, in the PTU control group, the number of hepatocytes per unit area was significantly (p <0.01) decreased by swelling of the hepatocytes due to remarkable invasion of lipid droplets compared with the normal medium control group. The hepatocyte swelling was significantly inhibited by LT4 0.5 mg / kg, AL mix 400 and 200 mg / kg. That is, the number of liver cells per unit area (p <0.01) was significantly increased in the LT 4 0.5 mg / kg, AL mix 400 and 200 mg / kg administration groups, respectively, as compared with the PTU control group. On the other hand, in the AL mix 100 mg / kg group, significant hepatic histopathological changes compared with the PTU control group did not show any change in the number of hepatocytes per unit area.

The number of liver cells per unit area was -54.25% compared to the normal medium control group in the PTU control group, but 75.36% in the LT4 0.5 mg / kg, AL mix 400, 200 and 100 mg / , 82.32, 38.42 and 5.30%, respectively.

In addition, histopathological changes of the testes were confirmed and are shown in Table 11 and FIG.

As shown in Table 11 and FIG. 7, in the PTU control group, significant canalicular atrophy and spermatogenesis were significantly suppressed in the control group compared to the normal medium control group, and significant differences (p <0.01) Stimulation of stage I and II spermatocytes showing mature spermatozoa was observed. However, inhibition of spermatogenesis and spermatogenesis by PTU administration was significantly inhibited by oral administration of AL mix 400 and 200 mg / kg, respectively. In the AL mix 400 and 200 mg / kg administration groups, the mean diameter of the tubules and the number of stage I to II tubules showing mature sperm were significantly (p <0.01 or p <0.05) higher than those of the PTU control group, respectively. On the other hand, in the LT4-treated group, the mean tubular diameter decreased significantly (p <0.01) compared to the PTU-treated group (p <0.05) There was no significant change in mean tubular diameter and stage I to II tubule ratio in mature spermatozoa compared with PTU control group.

The average tubular diameter of the PTU group was -34.32% compared to the normal control group. However, in the LT 4 0.5 mg / kg, AL mix 400, 200 and 100 mg / kg groups, , 24.11, 14.73 and 3.12%, respectively.

The ratio of stage I to II positive tubules showing mature spermatozoa was -59.06% in the PTU control group compared with the normal medium control group. However, in the LT 4 0.5 mg / kg, AL mix 400, 200 and 100 mg / Compared with the control group, the changes were -61.50, 88.05, 67.62 and 4.87%, respectively.

In addition, histopathological changes of the epididymis were confirmed and are shown in Table 11 and FIG.

As shown in Table 11 and FIG. 8, in the PTU control group, significant atrophy of the epididymal head and decrease in the number of spermatozoa in the conduit were recognized compared to the normal medium control group, and significant (p <0.01) However, epididymal atrophy and conduit spermatogenesis by PTU administration were significantly inhibited by oral administration of AL mix 400 and 200 mg / kg, respectively, although the decrease in diameter was accompanied by an increase in the ratio of the epididymal duct showing decreased spermatogenesis. That is, in the AL mix 400 and 200 mg / kg administration groups, an increase in the average diameter of the epididymal cephalad compared with the PTU control (p <0.01 or p <0.05) was recognized with a decrease in the ratio of the epididymal duct showing decreased spermatogenesis. On the other hand, in the LT4-treated group, the mean diameter of the epididymal head was similar to that of the PTU control group. However, the ratio of the epididymal duct showing increased spermatogenesis was significantly (p <0.01) There was no significant change in the mean diameter of the epididymal cephalad compared with the PTU control and the change of the epididymal duct ratio indicating spermatogenesis.

The average diameter of epididymal tofu was -20.37% compared to the normal medium control group in the PTU control group, but -0.02 in the LT4 0.5 mg / kg, AL mix 400, 200 and 100 mg / , 16.26, 11.80 and 3.31%, respectively.

The proportion of epididymal ducts showing spermatogenesis was 928.76% in PTU control group compared with PTU control group, but in LT 4 0.5 mg / kg, AL mix 400, 200 and 100 mg / , -59.24, -38.54 and -2.55%, respectively.

In addition, histopathological changes of the prostate gland were confirmed and are shown in Table 11 and Fig.

As shown in Table 11 and FIG. 9, in the PTU control group, prominent prostatic conduit atrophy was recognized as compared with the normal medium control group, and the decrease in the average thickness of the prostate duct epithelium was significant (p <0.01) Prostate atrophy by PTU administration was significantly inhibited by AL mix 400 and 200 mg / kg oral administration. In the AL mix 400 and 200 mg / kg administration groups, an increase in the mean thickness of the prostate duct epithelium (p <0.01) as compared to the PTU control was recognized with a decrease in the atrophic conduit ratio. On the other hand, the mean thickness of the prostate canal epithelium and the rate of atrophy of the atrioventricular duct were significantly increased (p <0.01) in the LT4 group compared to the PTU control group. In the AL mix 100 mg / kg group, No change in the mean thickness of the ductal epithelium and the rate of the atrophic duct was observed.

The mean thickness of the prostate duct epithelium was -66.85% compared to the normal medium control group in the PTU control group. However, in the LT 4 0.5 mg / kg, AL mix 400, 200 and 100 mg / 42.38, 90.38, 38.28 and 2.74%, respectively.

The proportion of prostate ducts showing atrophic changes was 1347.06% in the PTU control group compared with the PTU control group in the LT 4 0.5 mg / kg, AL mix 400, 200 and 100 mg / kg administration groups, respectively. , -68.50, -42.68 and -5.49%, respectively

As a result of the above experiment, significant decrease in body weight, increase in thyroid weight, decrease in liver, testicles, prostate and epididymal weight, decrease in T3 and T4 content in serum and TSH content in subcutaneous administration of PTU 10 mg / , Increased testosterone and DHT content, increased FSH content, increased HDL content and decreased triglyceride content, impaired liver and testis antioxidant defense system, and elevated serum AST levels, The histopathologic findings were as follows: hyperplasia due to enlargement of thyroid follicular cells, decrease of hepatic cells per unit area due to hypertrophy of hepatocyte lipid infiltration, increase in number of epididymal ducts showing epididymal atrophy and spermatogenesis, And mature spermatozoa, and a marked decrease in prostate conduits were observed.

On the other hand, the oral administration of AL mix 400 and 200 mg / kg significantly inhibited the PTU-induced hypothyroidism in a dose-dependent manner, and the changes in the relevant blood lipid levels and liver and testosterone antioxidant defense system However, in the AL mix 100 mg / kg group, the protective effect against the hypothyroidism, the related blood lipid changes, and the liver and the reproductive disorder were not observed in comparison with the PTU control group. These results indicate that oral administration of AL mix 400 and 200 mg / kg, at least under the conditions of this experiment, resulted in decreased body weight, decreased thyroid gland, thyroid and sex hormone levels, It is expected that the appropriate dose of AL mix will be developed as a new thyroid function improver in the future, as it is judged to be a very effective control of change, liver and genital damage by controlling the antioxidant defense system. On the other hand, LT4 administration markedly suppressed hypothyroidism and related changes in blood lipid content and liver damage, but testicular, prostate, and epididymal, ie, reproductive damage, was further exacerbated. In particular, Worsening was recognized.

In general, hypothyroidism is characterized by a delay in metabolism due to insufficient secretion of thyroid hormone and a decrease in catabolism, resulting in the accumulation of glycoproteins in tissues. However, it is known that weight gain is compensated for by hypothyroidism It is known that leptin secretion increases, appetite decreases, energy metabolism increases, and weight loss may be induced. In addition, it is known that administration of PTU of 10 mg / kg or more in laboratory animals leads to a significant decrease in body weight , PTU-induced hypothyroidism in rats has been known to cause a general decrease in body weight in general.

In the present study, significant weight loss in the PTU control group began to be recognized from 2 weeks after administration of PTU, and the amount of body weight gain during the 4-week PTU administration period and the 6-week experimental period also decreased significantly compared with the normal control group Respectively. On the other hand, in the LT4-treated group, a significant increase in body weight was observed from the third week after the PTU administration to the PTU control, and the body weight gain during the PTU administration period and the pre-experiment period was significantly increased compared to the PTU control group. And 200 mg / kg, respectively, significant weight gain was observed from the 35th day after the administration of PTU compared with the PTU control, and the increase of the body weight gain during the PTU administration period and the experimental period was recognized as compared with the PTU control. On the other hand, in the AL mix 100 mg / kg administration group, significant changes in body weight and body weight were not observed compared with the PTU control group. Therefore, oral administration of AL mix of 200 mg / kg or more seems to effectively inhibit the decrease of body weight caused by PTU-induced hypothyroidism.

PTU inhibits the binding of iodine and tyrosine as a typical thyroid inhibitor, inducing an absolute decrease in T3 and T4 with an increase in TSH, leading to inactive thyroid gland enlargement (simple goiter) and a histopathologically significant thyroid gland The enlargement of follicular cells and the decrease of follicle diameter and follicle colloid material are characteristic. In the present study, histopathologic changes such as enlargement of thyroid gland and enlargement of thyroid follicular cells, decrease of follicular diameter and colloid material in follicles, that is, typical inactive thyroid enlargement were recognized in PTU control group , Histopathologic changes of thyroid weight and inactive thyroid enlargement were significantly inhibited by LT4 0.5 mg / kg, AL mix 400 and 200 mg / kg. Mean thyroid weight and histopathological changes were not observed in the AL mix 100 mg / kg group. These results suggest that the AL mix is one of the clearest evidence to directly inhibit PTU-induced thyroid changes at doses of 200 and 400 mg / kg, at least under the conditions of this experiment.

The TSH, T3 and T4 contents of serum are mainly used as a functional test of thyroid gland. TSH, T4 and T3 are diagnosed as hypothyroidism. The results of this experiment also showed that the PTU group showed a marked reduction of T3 and T4 with an increase of TSH. On the other hand, decrease of TSH content and normalization of T4 content were recognized by administration of LT4, but there was no difference in T3 content, whereas in AL mix 400 and 200 mg / k group, decrease of TSH content and increase of T4 content were recognized And the T3 content was also significantly increased. On the other hand, significant changes in serum thyroid hormone levels were not observed in the AL mix 100 mg / kg group. These results suggest that, under conditions of at least this experiment, AL mix thus not only compensates for reduced T4 content, but also changes the thyroid follicle cells through the activity of the antioxidant defense system, unlike LT4, at doses of 200 and 400 mg / kg Inhibitory effect, suggesting a very effective effect on hypothyroidism, but the precise mechanism is unknown in this experiment. Therefore, it is considered that various studies of various mechanisms should be carried out in the future.

Thyroid hormones inhibit lipid metabolism and cholesterol synthesis in the liver, causing changes in serum lipid levels. It is known that the abnormality of lipoproteins commonly known is caused by the increase of TC and LDL contents, resulting in complications of the vascular system, and it is known that LT4 administration significantly inhibits the lipid protein. However, the lipid change in the serum indicates the state of the thyroid hormone , And it is known that it is directly related to the change of antioxidant defense system. Therefore, there is a wide variety of serum lipid content changes depending on the degree and timing of hypothyroidism and other complications. As a result of this experiment, changes of TC and LDL in serum were not recognized by PTU administration, but TG decreased with increasing HDL. On the other hand, significant reduction of HDL and TG content in the serum compared to the PTU control group was recognized in the LT4 0.5 mg / kg, AL mix 400 and 200 mg / kg administration groups by the increase of the thyroid hormone content, The function is normalized, and the use of lipid is increased. On the other hand, there was no significant change in blood lipid - TC, LDL, HDL and TG contents in the AL mix 100 mg / kg group compared to the PTU control group. These results are considered to be one of the clear evidences of excellent blood lipid-lowering effects of AL mix 200 and 400 mg / kg on PTU-induced hypothyroidism rats.

Liver is a typical organs affected by thyroid hormone, and it is known that hypothyroidism accompanies time-related damage. AST and ALT are enzymes present in hepatocytes. Elevation of serum levels of these enzymes is used as an index of liver damage. Significant serum elevation of these enzymes is observed even in hypothyroidism, and PTU-administered hyperthyroidism An increase of these enzymes is recognized in 30% of patients. On the other hand, in some studies, it is also known that AST levels are increased only without elevation of ALT levels, and a decrease in liver cells per unit area due to hypertrophy of hepatocytes in microstructure is recognized. Similar to previous studies, a decrease in hepatic weight and a significant increase in AST content in blood and a decrease in hepatocyte per unit area due to hypertrophy due to hepatocyte lipid infiltration were induced by PTU administration, but significant Changes in ALT content were not observed. On the other hand, in the LT 4 0.5 mg / kg, AL mix 400 and 200 mg / kg administration groups, the liver damage effect by the PTU administration was remarkably suppressed, but significant liver protection effect was not observed in the AL mix 100 mg / kg administration group. These results are conclusive evidence that the protective effect against liver damage caused by PTU-induced hypothyroidism in AL mix at doses of 200 and 400 mg / kg, at least under the conditions of this experiment.

Recently, a decrease in the basal metabolic rate has suppressed cellular respiration, suppressed lipid peroxidation, and increased the SOD and a significant decrease in CAT, and accumulation of H2O2 in the liver tissue, And antioxidant defensive system. It is known that hypothyroidism symptoms are significantly reduced by the administration of antioxidants. Accordingly, the development of a therapeutic agent for hypothyroidism derived from natural materials, which exhibits a strong antioxidative effect, has attracted attention. The results of this experiment are consistent with the previous studies. In addition to a slight decrease in lipid peroxidation and a slight increase in SOD activity, which is a typical endogenous antioxidant enzyme, PTO administration, a significant cellular respiratory oxidant H2O2 , But oral administration of AL mix 400 and 200 mg / kg inhibited the activity of SOD in a similar manner to the LT4 alone composition, but the increase of CAT activity relative to H 2 O 2 accumulation As shown in Fig. On the other hand, no significant change in liver lipid peroxidation and antioxidant defense system was observed in the AL mix 100 mg / kg administration group. These results indicate direct and reliable evidence of strong antioxidant effects in AL mix 200 and 400 mg / kg of PTU-induced hypothyroidism in rats.

The testes are physiologically performing two important high-energy constitutive activities, such as steroidogenesis and spermato-genesis, which are higher in content of polyunsaturated fatty acids than other organs, Defense systems are known to be particularly vulnerable to peroxidation factors such as weakness, smoking, polychlorinated biphenyls, hydrocarbons and drinking. Oxidative stress of the testes is known to be an important factor of male infertility and it is known that the spermatozoon changes the number of spermatozoa. Therefore, the body's thyroid hormone content and male infertility are closely related, and it is known that changes in antioxidant defense system in the testes are involved in this. Testicular is also known to be a typical organs affected by thyroid hormones. It is accompanied by a significant decrease in testosterone and DHT and an increase in FSH content, as well as significant atrophy in hypothyroidism. On the other hand, the epithelium of the canaliculus is classified into 6 stages according to the spermatogenesis process. In order to observe the change of spermatogenesis in the present study, The proportion of stage I to II cannulae containing mature spermatozoa in the canals was measured. As a result of this experiment, similar to the previous studies, PTU administration reduced testicular, epididymal and prostate weight and male hormone levels, and also resulted in depletion of the testosterone antioxidant defense system, epididymal atrophy, Increased number of ducts, atrophy of testicular tubules, and reduced rate of stage I to II positive tubules containing mature sperm and prominent atrophy of the prostate duct were recognized histopathologically, but PTU induced genital disorders and antioxidant defensive system decreased AL mix 200 and 400 mg / kg, respectively. On the other hand, similar to previous reports, the LT4-treated group caused an increase in genital damage due to deterioration of the antioxidant defense system, and no significant reproductive organ protection effect was observed in the AL mix 100 mg / kg group. These results are at least accurate and direct evidence of the inhibition of PTU-induced genital disorder through control of antioxidant defense systems at AL mix 200 and 400 mg / kg, at least under the conditions of this experiment.

While the present invention has been particularly shown and described with reference to exemplary embodiments thereof, it is to be understood that the same is by way of illustration and example only and is not to be construed as limiting the scope of the present invention. Accordingly, the actual scope of the present invention will be defined by the appended claims and their equivalents.

Claims (8)

Sea tangle ( Laminaria japonica ) and astragalus membranaceus as an active ingredient. The composition for improving or preventing thyroid disease according to claim 1, The method according to claim 1,
Wherein the at least one extract selected from the group consisting of kelp and yellow radish is a hot-water extract of a mixture of kelp and sulfur. The method according to claim 1,
Wherein the at least one extract selected from the group consisting of kelp and kelp is a mixture of kelp and hwanggi at a weight ratio of 3: 1 (kelp: kelp), and water is added and extracted by hot water extraction. Food composition for prevention. The method according to claim 1,
The food composition for improving or preventing thyroid disease is a health functional food for improving or preventing thyroid disease. The method according to claim 1,
Wherein the thyroid disease is hypothyroidism. Sea tangle ( Laminaria japonica ) and Astragalus membranaceus as an effective ingredient. The present invention also provides a pharmaceutical composition for treating or preventing thyroid disease. The method according to claim 6,
Wherein at least one of the extracts selected from the group consisting of kelp and hwanggi is a mixture of kelp and hwanggi at a weight ratio of 3: 1 (kelp: hwanggi), and water is added and extracted by hot water extraction. Or a pharmaceutically acceptable salt thereof. The method according to claim 6,
Wherein the thyroid disease is hypothyroidism.

Images